cysteamine + zidovudine

**Cysteamine + zidovudine** is a theoretical or investigational **combination of two drugs**: cysteamine, a small molecule antioxidant and cystine-depleting agent, and zidovudine, an antiretroviral medication belonging to the class of nucleoside reverse transcriptase inhibitors (NRTIs). Cysteamine is primarily approved for use in nephropathic cystinosis where it reduces intracellular cystine accumulation, while zidovudine (also known as AZT) is approved for the treatment of HIV infection by inhibiting viral reverse transcriptase and halting viral DNA synthesis. As of the information available, there is no marketed product, brand, or widely recognized clinical evidence for a fixed-dose combination or co-packaged formulation of cysteamine + zidovudine. Developmental or research use, if any, would likely be for novel or adjunct indications such as investigating cysteamine's potential adjuvant role in antiretroviral regimens. The **mechanism of action** for such a combination would derive from the individual activities of its components.